Sclerosis [clinicaltrials_resource:1e82e869a34acfb96778f722024ab375]
Assessment of Patients With Multiple Sclerosis (MS) [clinicaltrials:NCT00001156]Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS) [clinicaltrials:NCT00001248]A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients [clinicaltrials:NCT00001669]Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS) [clinicaltrials:NCT00001781]Zenapax to Treat Multiple Sclerosis [clinicaltrials:NCT00001934]Study of Skin Tumors in Tuberous Sclerosis [clinicaltrials:NCT00001975]Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis [clinicaltrials:NCT00004380]Determinants of Disease Severity in Amyotrophic Lateral Sclerosis [clinicaltrials:NCT00004457]Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone [clinicaltrials:NCT00004645]Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis [clinicaltrials:NCT00004744]Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis [clinicaltrials:NCT00004786]Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis [clinicaltrials:NCT00004814]A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple Sclerosis [clinicaltrials:NCT00004816]Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS] [clinicaltrials:NCT00005674]Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [clinicaltrials:NCT00005766]Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis [clinicaltrials:NCT00006060]Genetic Study of the FBN1 Gene and Fibrillin-1 Abnormalities in Choctaw Native Americans and Other Patients With Systemic Sclerosis [clinicaltrials:NCT00006393]Amyotrophic Lateral Sclerosis (ALS) Gulf War Study [clinicaltrials:NCT00007722]Natural Antioxidants in the Treatment of Multiple Sclerosis [clinicaltrials:NCT00010842]Yoga: Effect on Attention in Aging & Multiple Sclerosis [clinicaltrials:NCT00010998]Rolipram to Treat Multiple Sclerosis [clinicaltrials:NCT00011375]Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis [clinicaltrials:NCT00014755]Screening and Natural History: Primary Lateral Sclerosis and Related Disorders [clinicaltrials:NCT00015444]Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis [clinicaltrials:NCT00016458]Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis [clinicaltrials:NCT00017628]Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS [clinicaltrials:NCT00021697]Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis [clinicaltrials:NCT00023075]Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis [clinicaltrials:NCT00027300]Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis [clinicaltrials:NCT00030966]A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis [clinicaltrials:NCT00035529]clinicaltrials:NCT00035815A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis [clinicaltrials:NCT00036413]Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis [clinicaltrials:NCT00037102]Auditory Function in Patients With and Without Multiple Sclerosis [clinicaltrials:NCT00037947]clinicaltrials:NCT00039988High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis [clinicaltrials:NCT00040482]Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients [clinicaltrials:NCT00040651]Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis [clinicaltrials:NCT00043264]Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis [clinicaltrials:NCT00043706]Minocycline to Treat Amyotrophic Lateral Sclerosis [clinicaltrials:NCT00047723]
condition browse [clinicaltrials_vocabulary:condition-browse]
Assessment of Patients With Multiple Sclerosis (MS) [clinicaltrials:NCT00001156]Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS) [clinicaltrials:NCT00001248]A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients [clinicaltrials:NCT00001669]Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS) [clinicaltrials:NCT00001781]Zenapax to Treat Multiple Sclerosis [clinicaltrials:NCT00001934]Study of Skin Tumors in Tuberous Sclerosis [clinicaltrials:NCT00001975]Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis [clinicaltrials:NCT00004380]Determinants of Disease Severity in Amyotrophic Lateral Sclerosis [clinicaltrials:NCT00004457]Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone [clinicaltrials:NCT00004645]Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis [clinicaltrials:NCT00004744]Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis [clinicaltrials:NCT00004786]Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis [clinicaltrials:NCT00004814]A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple Sclerosis [clinicaltrials:NCT00004816]Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS] [clinicaltrials:NCT00005674]Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [clinicaltrials:NCT00005766]Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis [clinicaltrials:NCT00006060]Genetic Study of the FBN1 Gene and Fibrillin-1 Abnormalities in Choctaw Native Americans and Other Patients With Systemic Sclerosis [clinicaltrials:NCT00006393]Amyotrophic Lateral Sclerosis (ALS) Gulf War Study [clinicaltrials:NCT00007722]Natural Antioxidants in the Treatment of Multiple Sclerosis [clinicaltrials:NCT00010842]Yoga: Effect on Attention in Aging & Multiple Sclerosis [clinicaltrials:NCT00010998]Rolipram to Treat Multiple Sclerosis [clinicaltrials:NCT00011375]Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis [clinicaltrials:NCT00014755]Screening and Natural History: Primary Lateral Sclerosis and Related Disorders [clinicaltrials:NCT00015444]Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis [clinicaltrials:NCT00016458]Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis [clinicaltrials:NCT00017628]Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS [clinicaltrials:NCT00021697]Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis [clinicaltrials:NCT00023075]Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis [clinicaltrials:NCT00027300]Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis [clinicaltrials:NCT00030966]A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis [clinicaltrials:NCT00035529]clinicaltrials:NCT00035815A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis [clinicaltrials:NCT00036413]Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis [clinicaltrials:NCT00037102]Auditory Function in Patients With and Without Multiple Sclerosis [clinicaltrials:NCT00037947]clinicaltrials:NCT00039988High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis [clinicaltrials:NCT00040482]Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients [clinicaltrials:NCT00040651]Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis [clinicaltrials:NCT00043264]Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis [clinicaltrials:NCT00043706]Minocycline to Treat Amyotrophic Lateral Sclerosis [clinicaltrials:NCT00047723]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
Sclerosis [clinicaltrials_resource:1e82e869a34acfb96778f722024ab375]
Bio2RDF identifier
1e82e869a34acfb96778f722024ab375
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:1e82e869a34acfb96778f722024ab375
identifier
clinicaltrials_resource:1e82e869a34acfb96778f722024ab375
title
Sclerosis
@en
type
label
Sclerosis [clinicaltrials_resource:1e82e869a34acfb96778f722024ab375]
@en